Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 4 clinical trials
NUVOLA TRIAL Open-label Multicentre Study

Combination of intermittent olaparib with weekly carboplatin and paclitaxel might achieve a higher pathological response rate, with an acceptable toxicity profile.

follicle stimulating hormone
hysterectomy
white blood cell count
neutrophil count
adp-ribose
  • 0 views
  • 19 Feb, 2024
  • 1 location
Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer

A study to assess the efficacy and safety of durvalumab in combination with platinum-based chemotherapy (paclitaxel + carboplatin) followed by maintenance durvalumab with or without olaparib for patients with newly diagnosed advanced or recurrent endometrial cancer.

adjuvant
sarcoma
endometrial carcinoma
platinum-based chemotherapy
carcinoma
  • 0 views
  • 19 Feb, 2024
  • 95 locations
Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)

The purpose of this study is to assess the efficacy and safety of pembrolizumab in combination with concurrent chemoradiation therapy followed by either pembrolizumab with olaparib placebo (Arm 1) or with olaparib (Arm 2) compared to concurrent chemoradiation therapy followed by durvalumab (Arm 3) in participants with unresectable, locally advanced …

adjuvant
metastasis
stage iv nsclc
pembrolizumab
stage iv non-small cell lung cancer
  • 0 views
  • 19 Feb, 2024
  • 14 locations
Delayed Initiation of Olaparib Maintenance Therapy in Platinum Sensitive Recurrent Ovarian Cancer

The purpose of this study is to test if delaying the start of the olaparib until there is a rise in a tumor marker called CA-125 will result in a longer time until the next or different treatment for the patient's cancer.

blood transfusion
remission
maintenance therapy
tumor markers
ovarian cancer
  • 0 views
  • 19 Feb, 2024
  • 1 location